FIRST AUTHOR INDEX |
Last Name |
First Name |
No. |
Title |
Harvey |
Philip |
SL-1 |
Newest Developments in the Assessment and Treatment of Cognition and Disability in Schizophrenia |
Manji |
Husseini K. |
SL-2 |
Targeting Synaptic & Neural Plasticity to Develop Improved Rx’s for Severe Mood Disorders |
Kim |
Hyoung-Chun |
S10-1 |
Role of IL-6 in the neurotoxicity and cognitive dysfunction induced by convulsant |
Saito |
Kuniaki |
S10-2 |
The role of L-tryptophan metabolism via indoleamine 2,3-dioxygenase on cytokine-induced depressive symptoms |
Yamada |
Kiyofumi |
S10-3 |
Molecular mechanism of neurodevelopmental disorders associated with perinatal aberrant neuroimmune responses |
Niwa |
Minae |
S10-4 |
Dopaminergic disturbance and behavioral deficits in mental illness: Roles of stress and glucocorticoids |
Kato |
Takahiro |
S10-5 |
Psychosocial stress and microglia-translational research focusing on human microglia |
Kimura |
Hiroshi |
PJ-1 |
A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis |
Takeuchi |
Hiroyoshi |
PJ-2 |
Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients with Schizophrenia: An Open-label, Randomized, Controlled, Pilot Study |
Suzuki |
Yutaro |
EN-3 |
Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia |
Harvey |
Philip |
LS07 |
The Role of the dopamine D3 receptor in Cognition and Disability in Schizophrenia |
Andersen |
Peter Høngaard |
AS01 |
Development of the curative medicine to the psychiatric disorders (especially depression, mood disorders) by industrial, administrative and academic sectors cooperation |
Kane |
John M. |
SpS4-1 |
Consider the therapeutic goals: Recovery |
Tsuboi |
Takashi |
O1-E2 |
Challenging the Need for High and Sustained Dopamine D2 Receptor Blockade in the Maintenance Treatment of Schizophrenia: A Single-Blind, Randomized, Controlled Study |
Ishioka |
Masamichi |
O1-F6 |
Hyperprolactinemia during antipsychotic treatment increases the risk for venous thromboembolism |
Tsuneyama |
Nobuto |
O1-F7 |
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia |
Shinfuku |
Masaki |
O1-F9 |
Effectiveness of Long-term Benzodiazepine Use in Anxiety Disorders: A Systematic Review |
Moriya |
Shunpei |
O3-F2 |
Effect of quetiapine on Per1, Per2, and Bmal1 clock gene expression in the mouse amygdala and hippocampus |
Odagaki |
Yuji |
O3-F9 |
Selective interaction between adenosine receptors and Gi-3 in postmortem human brain membranes |
Mizoguchi |
Kazushige |
O3-F13 |
Specific binding and characteristics of 18β-glycyrrhetinic acid in the rat brain |
Kato |
Masaki |
P1-1 |
Genome-wide interaction and pathway analysis on SSRI response in Japanese patient with major depression |
Matsumoto |
Yoshihiko |
P1-4 |
Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder |
Kishi |
Taro |
P1-7 |
The Position of Blonanserin as a Treatment for Schizophrenia |
Kishi |
Taro |
P1-8 |
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
Harvey |
Philip |
P1-13 |
IMPACT OF IMPROVED INSIGHT IN SCHIZOPHRENIA: A DOUBLE-BLIND LURASIDONE AND QUETIAPINE XR STUDY |
Oya |
Kazuto |
P1-19 |
Efficacy and Tolerability of Minocycline Augmentation Therapy in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Oya |
Kazuto |
P1-20 |
Efficacy and Tolerability of Histamine-2 Receptor Antagonist Adjunction of AntipsychoticTreatment in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials |
Uchida |
Hiroyuki |
P1-22 |
Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications |
Siu |
Cynthia |
P1-26 |
Insight into illness and uncooperativeness in chronic schizophrenia |
Suzuki |
Yutaro |
P1-32 |
Effects of olanzapine on the PR and QT intervals in patients with schizophrenia |
Saito |
Mami |
P1-39 |
High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia |
Tarumi |
Ryosuke |
P1-43 |
The evolution of augmentation therapy in the treatment of depression: a chart review |
Ueno |
Fumihiko |
P1-45 |
Whether to increase or maintain dosage of mirtazapine in early non-improvers with depression |
Yoshida |
Kazunari |
P1-50 |
Population pharmacokinetic analysis of lithium: a preliminary study |
Matsunaga |
Shinji |
P1-59 |
Memantine Monotherapy for Alzheimer's disease: A Systematic Review and Meta-analysis |
Sasaki |
Tsuyoshi |
P1-63 |
Tipepidine in children with attention deficit/ hyperactivity disorder: a 4-week, open-label, preliminary study |
Ogasa |
Masaaki |
P1-95 |
VALIDITY CHARACTERISTICS OF COGNITIVE ASSESSMENT INTERVIEW (CAI) IN STABLE OUTPATIENTS WITH SCHIZOPHRENIA |
Mizoguchi |
Kazushige |
P2-19 |
Specific binding and characteristics of geissoschizine methyl ether, an alkaloid of Uncaria Hook, in the rat brain |
Oshibuchi |
Hidehiro |
P2-39 |
CHRONIC HYPOACTIVITY OF RAPHE SEROTONERGIC NEURONS INHIBITS COCAINE SENSITIZATION; A STUDY USING DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED DESIGNER DRUGS |
Shimizu |
Kunio |
P2-41 |
Environmental Enrichment enhances hippocampal autophagy signaling in a rat animal model of posttraumatic stress disorder using a shuttle box |
Nagasawa |
Sarah |
P2-42 |
The effectiveness of methylphenidate and atomoxetine in the dopamine transporter knockout (DAT-KO) mice by postnatal development |
Moriguchi |
Shigeki |
P2-44 |
Function of decreased Na+/Ca2+ exchanger type 2 in AD model mice |
Yamada |
Makiko |
P2-53 |
Effects of escitalopram on the amygdala dopamine release in the stress-sensitive rats |
Mizuno |
Yuya |
P2-66 |
Biological and Clinical Correlates of Resilience in Patients with Schizophrenia: A Cross-sectional Study |